Coexistence of COPD or asthma in patients with bronchiectasis: a systematic review and meta-analysis Authors: Yuhua Wen, Yuwei Zhang, Yan Chen, Rui Fan Published: 2026 ABSTRACT BackgroundBronchiectasis frequently coexists with other chronic airway diseases, particularly chronic obstructive pulmonary disease (COPD) and asthma, forming clinically significant bronchiectasis–COPD overlap and bronchiectasis–asthma overlap phenotypes. However, the global proportion of COPD and asthma among patients with bronchiectasis has not been comprehensively quantified. This study aimed to estimate the pooled proportion of COPD and asthma in bronchiectasis and to explore potential sources of heterogeneity.MethodsPubMed, Embase, and Web of Science were systematically searched up to January 8, 2026. Studies reporting the proportion of COPD or asthma in adults with bronchiectasis confirmed by high-resolution computed tomography were eligible. Random-effects models were used to calculate pooled proportions. Subgroup analyses and meta-regression were performed to explore heterogeneity. Publication bias was assessed using funnel plots and Egger’s test.ResultsFifty-two studies (81,779 patients) were included for COPD and 47 studies (71,605 patients) for asthma. The pooled proportion of COPD among bronchiectasis patients was 18% (95% CI: 14–22%; I² = 99.4%), and the pooled proportion of asthma was 16% (95% CI: 11–20%; I² = 99.3%). Subgroup analyses revealed variations by geographic region, study design, and age. Meta-regression identified female proportion as a statistically significant but weak predictor of asthma prevalence (β = 3.97, 95% CI: 0.91–7.03; P = 0.011), explaining only 10.6% of the between-study heterogeneity. No covariates significantly explained heterogeneity in COPD prevalence. Egger’s test showed no significant publication bias (COPD: P = 0.506; asthma: P = 0.153), and sensitivity analyses confirmed the stability of the findings.ConclusionsCOPD and asthma coexist in approximately one-fifth of patients with bronchiectasis, highlighting the importance of systematic assessment for these overlap syndromes. A weak association between female sex and asthma prevalence was observed, but this factor explained only a small fraction of the heterogeneity, indicating that other unmeasured variables are more important determinants. These findings support a more integrated, phenotype-driven approach to the management of chronic airway diseases.Trial registrationPROSPERO registration: CRD42023400445Supplementary InformationThe online version contains supplementary material available at 10.1186/s12890-026-04414-9. Introduction Chronic airway diseases, which commonly include bronchiectasis, chronic obstructive pulmonary disease (COPD), and asthma, are life-threatening pathological conditions with a proportion that is increasing globally [1, 2]. These diseases are characterized by airway inflammation, obstruction, and remodeling, resulting in repeated cough, sputum, wheezing, and shortness of breath [3, 4]. Bronchiectasis is diagnosed on the basis of clinical symptoms of cough, sputum, and recurrent respiratory tract infections and radiology [5]. In recent years, there has been growing recognition of the coexistence, or ‘overlap’, of bronchiectasis with other obstructive airway diseases, particularly COPD and asthma, prompting a need to better understand this clinical intersection. While the exact etiological relationship remains to be fully elucidated, it is hypothesized that chronic bronchial infection and persistent inflammation in COPD may lead to airway wall damage and subsequent bronchiectasis [6, 7]. The link with asthma is equally compelling; studies have demonstrated that up to one-third of patients with severe asthma exhibit radiological evidence of bronchiectasis on chest CT, suggesting that severe, uncontrolled airway inflammation may predispose individuals to structural airway damage [8, 9]. The coexistence of bronchiectasis with COPD or asthma represents a more severe clinical phenotype. Bronchiectasis tends to adversely affect the clinical status of patients with COPD, severely reducing their exercise capacity and quality of life and affecting their psychological status [10, 11]. Studies have shown that bronchiectasis is associated with an increased risk of exacerbations and is an independent risk factor for increased all-cause mortality in patients with COPD [12]. Previous meta-analyses have confirmed that patients with the bronchiectasis-COPD overlap exhibit greater daily sputum volume, more frequent exacerbations, poorer lung function, and elevated inflammatory biomarkers compared to those with COPD alone [13, 14]. Similarly, the presence of bronchiectasis appears to contribute to the severity of asthma. Recent studies have demonstrated that patients with asthma combined with bronchiectasis have more frequent exacerbations and more hospitalizations than patients with asthma alone [15]. The presence of bronchiectasis is associated with antibiotic consumption, severe pulmonary insufficiency, a high risk of tuberculosis, and a poor prognosis [16, 17]. Despite the recognized clinical impact of these overlap syndromes, a comprehensive and systematic summary of their proportion is lacking. To date, no meta-analysis has specifically quantified the global proportion of bronchiectasis patients who also have COPD or asthma, nor has any study systematically explored factors that may influence these estimates, such as geographic region, study design, age, or sex. This knowledge gap hinders accurate assessment of disease burden and limits the development of targeted screening and management strategies [18]. Therefore, this systematic review and meta-analysis aimed to: (1) provide reliable estimates of the proportion of bronchiectasis patients with coexisting COPD and asthma; and (2) explore potential sources of heterogeneity, including demographic and study-level characteristics, through subgroup and meta-regression analyses. By clarifying these proportions, we seek to inform clinical practice, guide resource allocation, and ultimately improve the personalized management of patients with these complex chronic airway diseases. Methods Search strategy A search of PubMed, Embase, and Web of Science was conducted to collect literature on bronchiectasis combined with COPD and bronchiectasis combined with asthma. A total of 18,655 articles were retrieved up to 8 January 2026, when the last database search was performed. The search strategy was as follows. Terms used for COPD included (Chronic Obstructive Lung Disease) OR (Chronic Obstructive Pulmonary Diseases) OR (COAD) OR (COPD) OR (Chronic Obstructive Airway Disease) OR (Chronic Obstructive Pulmonary Disease) OR (Airflow Obstruction, Chronic) OR (Airflow Obstructions, Chronic) OR (Chronic Airflow Obstructions) OR (Chronic Airflow Obstruction). Terms used for asthma included (Asthmas) OR (Bronchial Asthma) OR (Asthma, Bronchial). The search terms COPD and asthma were linked by “OR”. The terms used for bronchiectasis included (Bronchiectasis) OR (Bronchiectases), which were linked with “AND” and other search terms. This search strategy was adapted to accommodate other databases. During the search of these databases, all relevant research articles and reviews were also scrutinized to identify other potential data sources. This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. This meta-analysis was registered with the International Prospective Register of Systematic Reviews (PROSPERO) under registration number [CRD42023400445]. Inclusion and exclusion criteria The inclusion criteria were as follows: (1) asthma was defined according to the Global Initiative for Asthma (GINA) guidelines or other standard diagnostic criteria; (2) the diagnosis of COPD was consistent with accepted guidelines (e.g., GOLD criteria) requiring objective evidence of post-bronchodilator airflow obstruction (FEV₁/FVC < 0.7 or lower limit of normal); (3) HRCT confirmed bronchiectasis; (4) one or more demographic or clinicopathological characteristics, such as age and sex, were recorded; and (5) the study population was patients with bronchiectasis. The exclusion criteria were as follows: (1) duplicate publications of the same study; (2) investigation of a specific age group, such as children and adolescents; (3) reviews, conference papers, dissertations, case reports, and letters; (4) literature with incomplete or missing analytical data or logical errors; (5) the total study population was bronchiectasis–COPD overlap only or bronchiectasis–asthma overlap only; (6) non-English papers; and (7) animal experiments. Data extraction and quality assessment Two researchers independently searched and screened the literature, collected data, and cross-checked the data. If there were any disputes, they were resolved through discussion or negotiation with a third researcher. Data extraction included (1) basic information, such as the first author, time of publication, study population region, sample size, and age; (2) relevant data for calculating the proportion of bronchiectasis combined with COPD or asthma; and (3) relevant content for evaluating the risk of bias. Two researchers independently and separately assessed the quality of the included literature using the US Agency for Health Care Research and Development assessment quality criteria. Any disagreements were resolved by discussion or adjudicated by the third author. Data synthesis and analysis The meta-analysis was performed using R. Proportions were logit-transformed prior to pooling to stabilize variances and to ensure that confidence intervals remained within the 0–1 range. Between-study variance (τ²) was estimated using the restricted maximum likelihood (REML) method. The Hartung-Knapp adjustment was applied to the random-effects model to account for uncertainty in τ² estimation. In addition to confidence intervals, 95% prediction intervals were calculated for the primary outcomes to indicate the range within which the true proportion in a future study would be expected to fall, given the observed heterogeneity. Heterogeneity between the results of the included studies was analyzed using the χ2 test (test level, α = 0.1), while the magnitude of heterogeneity was determined quantitatively by combining I2. If I2 was < 50% and P > 0.1, there was no statistical heterogeneity among the studies, and then a meta-analysis was performed using the fixed-effects model. If this was not the case, a meta-analysis was performed using the random-effects model. Subgroup analyses were performed according to the type of study included, regional distribution, and age (with age ≥ 65 years as the cutoff). Geographic regions were classified as follows: Asia, Europe, North America (United States and Canada only; no eligible studies from Mexico were identified), and Oceania (Australia and New Zealand; no eligible studies from Pacific Island nations were identified). The presence of publication bias was determined on the basis of funnel plots combined with Egger’s test. Sensitivity analysis using a leave-one-out approach was performed to assess the stability of the pooled estimates. Meta-regression analyses were conducted to explore sources of heterogeneity, examining the effects of mean age, publication year, geographic region, study design, and female proportion. For categorical variables, overall significance was assessed using the Wald-type test. The proportion of between-study variance explained by covariates was quantified using R² analog statistic. Bubble plots were generated to visualize significant associations. Differences were considered statistically significant at P < 0.05. Results Study selection We searched 18,655 relevant documents from PubMed, Embase, and Web of Science databases, and abstracts of 12,882 records were screened after removing duplicate documents. The study selection process is shown in Fig. 1. A total of 459 studies were reviewed in full text by screening the titles and abstracts of the articles. We excluded 400 of these studies because they did not meet the criteria. 59 articles were finally determined to be eligible and were included in the study. Of these, 52 studies were on bronchiectasis–COPD overlap and 47 studies reported on bronchiectasis–asthma overlap. Fig. 1Flow chart of search strategy and study selection for systematic reviews and meta-analyses statement Flow chart of search strategy and study selection for systematic reviews and meta-analyses statement Study characteristics The basic characteristics of the comorbidity of bronchiectasis and COPD are shown in Table 1. There were 81,779 patients in the 52 studies of which 17 had a study population greater than 1,000. 20 studies were prospective and 30 were retrospective. 30 studies were conducted in Europe. The basic study characteristics of comorbidity of bronchiectasis-asthma are shown in Table 2. There were 71,605 patients included in the 47 studies of which 13 had a study population greater than 1,000. Of these, 17 studies were prospective and 30 were retrospective. Twenty-four studies were conducted in Europe and 20 were conducted in Asia. Table 1Characteristics of COPD and bronchiectasis studies included in this meta-analysisAuthors, yearPublication yearRegionStudy typeCOPD, nTotal bronchiectasis, nProportion of femaleAge(y), mean ± SDAliberti, S, et al. (2016) [19]2016Italy…retrospective12011450.60066Al-Kattan KM, et al. (2005) [20]2005Saudi Arabiaprospective11660.52029.9 ± 10.8Anwar GA, et al. (2013) [21]2013Englandprospective231890.51366.11Bellelli Giuseppe et al.(2016) [22]2016Britishprospective24912580.57566Borekci S, and Musellim B. (2021) [23]2021Turkeyretrospective63190.58649.0 ± 17.4Burgel PR, et al. (2025) [24]2025Franceretrospective986300.6666Buscot M, et al. (2016) [25]2016Franceretrospective322450.31060Çakır Edis E, et al. (2024) [26]2024Türkiyeprospective20210350.556.1 ± 16.1De La Rosa D, et al. (2016) [27]2016Spainretrospective704560.61267.2 ± 15.5De la Rosa D, et al. (2017) [28]2017Spainprospective15817900.54964.82 ± 18.38De Soyza A, et al. (2017) [29]2017UK…retrospective13917160.59766.43Despotes KA, et al. (2020) [30]2020USretrospective924960.83364.6 ± 13.3Dhar R, et al. (2019) [31]2019Indiaprospective11621950.43156Dimakou K, et al. (2016) [32]2016Greeceprospective182770.61460.5 ± 16Ewen R, et al. (2024) [33]2024Germanyprospective30710000.59358.43 ± 14.98Ferri S, et al. (2019) [34]2019Italyretrospective16570.70160.7 ± 12.3Finklea JD, et al. (2010) [35]2010USretrospective211730.69871.8 ± 11.8Goeminne PC, et al. (2012) [36]2012Belgiumretrospective655390.44567Goeminne PC, et al. (2014) [37]2014Belgiumprospective202450.51068Habesoglu MA, et al. (2011) [38]2011Turkeyretrospective231190.65057.0 ± 13.1Habesoglu MA, et al. (2011) [39]2011Turkeyretrospective563040.54356 ± 25Hakansson KE, et al. (2021) [40]2021Denmarkprospective652640.62066Huang HY, et al. (2020) [41]2020Taiwanretrospective228715,7290.54964.0 ± 14.8Hung CT, et al. (2018) [42]2018Chinaretrospective229235210.50263.63 ± 14.71Ielpo A, et al. (2020) [43]2020Spainprospective433540.60664.8 ± 15Jeong JH, et al. (2021)[44]2021Korearetrospective33610.75465.9 ± 8.83Kim SH, et al. (2021) [45]2021Korearetrospective4310050.41863.53 ± 7.58Kim SH, et al. (2021) [46]2021Korearetrospective2265980.55965.76Kumari MV, et al. (2016) [47]2016Indiaprospective2500.410Liu B, et al. (2018) [48]2018Chinaretrospective20818050.48555Lonni S, et al. (2015) [49]2015Italy…prospective25712580.60067Ma Giron R, et al. (2017) [50]2017Spainretrospective16420990.53661.0 ± 20.6Ma Y, et al. (2015) [51]2015Chinaretrospective501560.54465Ma Y, et al. (2020) [52]2020Chinaretrospective137154690.48164Martínez-García M, et al. (2020) [53]2020Italyretrospective611640.53065.7 ± 14.4Martínez-García MA, et al. (2021) [54]2021Spainretrospective20819120.63967.6 ± 15.2Martínez-García M, et al. (2014) [55]2014Spainprospective298190.56558.7 ± 17.6McDonnell MJ, et al. (2015) [56]2015UKretrospective161550.60662.1 ± 12.4Mehra S, et al. (2021) [57]2021Australiaretrospective2193880.58559Menéndez R, et al. (2017) [58]2017Spainprospective652650.60069.9Munteanu O, et al. (2016) [59]2016Moldovaprospective301650.44056.73 ± 14Olveira C, et al. (2017) [60]2017Spainretrospective16017920.54964.9 ± 18.4Pieters A, et al. (2019) [61]2019Netherlandsretrospective142110.54060Polverino E, et al. (2024) [62]2024Europeprospective432416,9630.60967.38Rademacher J, et al. (2019) [63]2019Germanyprospective15010000.59059 ± 16Rosales-Mayor E, et al. (2017) [64]2017Spainretrospective211820.59968.0 ± 14.6Scioscia G, et al. (2019) [65]2019Spainprospective361910.56572Sharif N, et al. (2020) [66]2020Pakistanprospective181960.235Terpstra LC, et al. (2019) [67]2019Netherlandsretrospective242000.57069.5 ± 10.3Venning V, et al. (2017) [68]2017Australiaretrospective36610.56066 ± 14Xu JF, et al. (2025) [69]2025Chinaprospective116010,3240.58263.1 ± 14.2Young S L, et al. (2021) [70]2021Singaporeprospective91680.67864 Table 1Characteristics of COPD and bronchiectasis studies included in this meta-analysisAuthors, yearPublication yearRegionStudy typeCOPD, nTotal bronchiectasis, nProportion of femaleAge(y), mean ± SDAliberti, S, et al. (2016) [19]2016Italy…retrospective12011450.60066Al-Kattan KM, et al. (2005) [20]2005Saudi Arabiaprospective11660.52029.9 ± 10.8Anwar GA, et al. (2013) [21]2013Englandprospective231890.51366.11Bellelli Giuseppe et al.(2016) [22]2016Britishprospective24912580.57566Borekci S, and Musellim B. (2021) [23]2021Turkeyretrospective63190.58649.0 ± 17.4Burgel PR, et al. (2025) [24]2025Franceretrospective986300.6666Buscot M, et al. (2016) [25]2016Franceretrospective322450.31060Çakır Edis E, et al. (2024) [26]2024Türkiyeprospective20210350.556.1 ± 16.1De La Rosa D, et al. (2016) [27]2016Spainretrospective704560.61267.2 ± 15.5De la Rosa D, et al. (2017) [28]2017Spainprospective15817900.54964.82 ± 18.38De Soyza A, et al. (2017) [29]2017UK…retrospective13917160.59766.43Despotes KA, et al. (2020) [30]2020USretrospective924960.83364.6 ± 13.3Dhar R, et al. (2019) [31]2019Indiaprospective11621950.43156Dimakou K, et al. (2016) [32]2016Greeceprospective182770.61460.5 ± 16Ewen R, et al. (2024) [33]2024Germanyprospective30710000.59358.43 ± 14.98Ferri S, et al. (2019) [34]2019Italyretrospective16570.70160.7 ± 12.3Finklea JD, et al. (2010) [35]2010USretrospective211730.69871.8 ± 11.8Goeminne PC, et al. (2012) [36]2012Belgiumretrospective655390.44567Goeminne PC, et al. (2014) [37]2014Belgiumprospective202450.51068Habesoglu MA, et al. (2011) [38]2011Turkeyretrospective231190.65057.0 ± 13.1Habesoglu MA, et al. (2011) [39]2011Turkeyretrospective563040.54356 ± 25Hakansson KE, et al. (2021) [40]2021Denmarkprospective652640.62066Huang HY, et al. (2020) [41]2020Taiwanretrospective228715,7290.54964.0 ± 14.8Hung CT, et al. (2018) [42]2018Chinaretrospective229235210.50263.63 ± 14.71Ielpo A, et al. (2020) [43]2020Spainprospective433540.60664.8 ± 15Jeong JH, et al. (2021)[44]2021Korearetrospective33610.75465.9 ± 8.83Kim SH, et al. (2021) [45]2021Korearetrospective4310050.41863.53 ± 7.58Kim SH, et al. (2021) [46]2021Korearetrospective2265980.55965.76Kumari MV, et al. (2016) [47]2016Indiaprospective2500.410Liu B, et al. (2018) [48]2018Chinaretrospective20818050.48555Lonni S, et al. (2015) [49]2015Italy…prospective25712580.60067Ma Giron R, et al. (2017) [50]2017Spainretrospective16420990.53661.0 ± 20.6Ma Y, et al. (2015) [51]2015Chinaretrospective501560.54465Ma Y, et al. (2020) [52]2020Chinaretrospective137154690.48164Martínez-García M, et al. (2020) [53]2020Italyretrospective611640.53065.7 ± 14.4Martínez-García MA, et al. (2021) [54]2021Spainretrospective20819120.63967.6 ± 15.2Martínez-García M, et al. (2014) [55]2014Spainprospective298190.56558.7 ± 17.6McDonnell MJ, et al. (2015) [56]2015UKretrospective161550.60662.1 ± 12.4Mehra S, et al. (2021) [57]2021Australiaretrospective2193880.58559Menéndez R, et al. (2017) [58]2017Spainprospective652650.60069.9Munteanu O, et al. (2016) [59]2016Moldovaprospective301650.44056.73 ± 14Olveira C, et al. (2017) [60]2017Spainretrospective16017920.54964.9 ± 18.4Pieters A, et al. (2019) [61]2019Netherlandsretrospective142110.54060Polverino E, et al. (2024) [62]2024Europeprospective432416,9630.60967.38Rademacher J, et al. (2019) [63]2019Germanyprospective15010000.59059 ± 16Rosales-Mayor E, et al. (2017) [64]2017Spainretrospective211820.59968.0 ± 14.6Scioscia G, et al. (2019) [65]2019Spainprospective361910.56572Sharif N, et al. (2020) [66]2020Pakistanprospective181960.235Terpstra LC, et al. (2019) [67]2019Netherlandsretrospective242000.57069.5 ± 10.3Venning V, et al. (2017) [68]2017Australiaretrospective36610.56066 ± 14Xu JF, et al. (2025) [69]2025Chinaprospective116010,3240.58263.1 ± 14.2Young S L, et al. (2021) [70]2021Singaporeprospective91680.67864 Characteristics of COPD and bronchiectasis studies included in this meta-analysis Table 2Characteristics of asthma and bronchiectasis studies included in this meta-analysisAuthors, yearPublication yearRegionStudy typeAsthma, nTotal bronchiectasis, nProportion of femaleAge(y), mean ± SDAliberti S, et al. (2016) [19]2016Italy….retrospective3511450.60066Anwar GA, et al. (2013) [21]2013Englandprospective61890.51366.11Banjar HH. (2007) [71]2007Saudi Arabiaretrospective1081510.503Borekci S, and Musellim B. (2021) [23]2021Turkeyretrospective203190.58649.0 ± 17.4Brill SE, et al. (2015)[72]2015UKprospective7320.84061 ± 12Burgel PR, et al. (2025) [24]2025Franceretrospective1486300.6666Buscot M, et al. (2016) [25]2016Franceretrospective102450.59060Çakır Edis E, et al. (2024) [26]2024Turkeyprospective21410350.556.1 ± 16.1Despotes KA, et al. (2020) [30]2020USretrospective1234960.83364.6 ± 13.3Dhar R, et al. (2019) [31]2019Indiaprospective5421950.43156Dimakou K, et al. (2016) [32]2016Greeceretrospective72770.61460.5 ± 16Ewen R, et al. (2024) [33]2024Germanyprospective29310000.59358.43 ± 14.98Ferri S et al. (2019) [34]2019Italyretrospective17570.70160.7 ± 12.3Guan WJ, et al. (2015) [73]2015Chinaprospective81480.62044.6 ± 13.8Habesoglu MA, et al. (2011) [38]2011Turkeyretrospective251190.65057.0 ± 13.1Habesoglu MA, et al. (2011) [39]2011Turkeyretrospective543040.54356 ± 25Hakansson KE, et al. (2021) [40]2021Denmarkprospective722640.62066Huang HY, et al. (2020) [41]2020Chinaretrospective166415,7290.60064.0 ± 14.8Ielpo A, et al. (2020) [43]2020Italyprospective363540.60064.8 ± 15Ip MS, et al. (1992) [74]1992Hong Kongretrospective23850.61249Jeong HJ, et al. (2016) [75]2016Korearetrospective281660.31964Jeong JH, et al. (2021) [44]2021Korearetrospective16610.75465.9 ± 8.83Kim SH, et al. (2021)[45]2021Korearetrospective4010050.41863.53 ± 7.58Kim SH, et al. (2021) [46]2021Korearetrospective1345980.55965.76Kumari MV, et al. (2016) [47]2016Indiaprospective2500.410Li L, et al. (2020) [76]2020Chinaretrospective131280.65657.13 ± 15.61Liu B, et al. (2018) [48]2018Chinaretrospective6118050.48555Lonni S, et al. (2015) [49]2015Italy…prospective4112580.60067Ma Giron R, et al. (2017) [50]2017Spainretrospective12320990.53661.0 ± 20.6Ma Y, et al. (2015) [51]2015Chinaretrospective361560.54065Ma Y, et al. (2020) [52]2020Chinaretrospective38254690.48164Mantyla J, et al. (2019) [77]2019Finlandretrospective65950.75069 ± 13Martínez-García M, et al. (2020) [53]2020Italyretrospective341640.53065.7 ± 14.4Martinez-García MA, et al. (2021) [54]2021Spainretrospective14919120.63967.6 ± 15.2McDonnell MJ, et al. (2015) [56]2015UKretrospective101550.60662.1 ± 12.4Mehra S, et al. (2021) [57]2021Australiaretrospective673880.58559Menéndez R, et al. (2017) [58]2017Spainprospective262650.60069.9Munteanu O, et al. (2016) [59]2016Moldovaprospective71650.44056.73 ± 14Olveira C, et al. (2017) [60]2017Spainretrospective11017920.54964.9 ± 18.4Pieters A, et al. (2019) [61]2019Netherlandsretrospective102110.54060Polverino E, et al. (2024) [62]2024Europeprospective526716,9630.60967.38Rademacher J, et al. (2019) [63]2019Germanyprospective11010000.59059 ± 16Rosales-Mayor E, et al. (2017) [64]2017Spainretrospective221820.59968.0 ± 14.6Scioscia G, et al. (2019) [65]2019Spainprospective131910.56572Venning V, et al. (2017) [68]2017Australiaretrospective27610.56066 ± 14Xu JF, et al. (2025) [69]2025Chinaprospective55810,3240.58263.1 ± 14.2Young SL, et al. (2021) [70]2021Singaporeprospective151680.67864 Table 2Characteristics of asthma and bronchiectasis studies included in this meta-analysisAuthors, yearPublication yearRegionStudy typeAsthma, nTotal bronchiectasis, nProportion of femaleAge(y), mean ± SDAliberti S, et al. (2016) [19]2016Italy….retrospective3511450.60066Anwar GA, et al. (2013) [21]2013Englandprospective61890.51366.11Banjar HH. (2007) [71]2007Saudi Arabiaretrospective1081510.503Borekci S, and Musellim B. (2021) [23]2021Turkeyretrospective203190.58649.0 ± 17.4Brill SE, et al. (2015)[72]2015UKprospective7320.84061 ± 12Burgel PR, et al. (2025) [24]2025Franceretrospective1486300.6666Buscot M, et al. (2016) [25]2016Franceretrospective102450.59060Çakır Edis E, et al. (2024) [26]2024Turkeyprospective21410350.556.1 ± 16.1Despotes KA, et al. (2020) [30]2020USretrospective1234960.83364.6 ± 13.3Dhar R, et al. (2019) [31]2019Indiaprospective5421950.43156Dimakou K, et al. (2016) [32]2016Greeceretrospective72770.61460.5 ± 16Ewen R, et al. (2024) [33]2024Germanyprospective29310000.59358.43 ± 14.98Ferri S et al. (2019) [34]2019Italyretrospective17570.70160.7 ± 12.3Guan WJ, et al. (2015) [73]2015Chinaprospective81480.62044.6 ± 13.8Habesoglu MA, et al. (2011) [38]2011Turkeyretrospective251190.65057.0 ± 13.1Habesoglu MA, et al. (2011) [39]2011Turkeyretrospective543040.54356 ± 25Hakansson KE, et al. (2021) [40]2021Denmarkprospective722640.62066Huang HY, et al. (2020) [41]2020Chinaretrospective166415,7290.60064.0 ± 14.8Ielpo A, et al. (2020) [43]2020Italyprospective363540.60064.8 ± 15Ip MS, et al. (1992) [74]1992Hong Kongretrospective23850.61249Jeong HJ, et al. (2016) [75]2016Korearetrospective281660.31964Jeong JH, et al. (2021) [44]2021Korearetrospective16610.75465.9 ± 8.83Kim SH, et al. (2021)[45]2021Korearetrospective4010050.41863.53 ± 7.58Kim SH, et al. (2021) [46]2021Korearetrospective1345980.55965.76Kumari MV, et al. (2016) [47]2016Indiaprospective2500.410Li L, et al. (2020) [76]2020Chinaretrospective131280.65657.13 ± 15.61Liu B, et al. (2018) [48]2018Chinaretrospective6118050.48555Lonni S, et al. (2015) [49]2015Italy…prospective4112580.60067Ma Giron R, et al. (2017) [50]2017Spainretrospective12320990.53661.0 ± 20.6Ma Y, et al. (2015) [51]2015Chinaretrospective361560.54065Ma Y, et al. (2020) [52]2020Chinaretrospective38254690.48164Mantyla J, et al. (2019) [77]2019Finlandretrospective65950.75069 ± 13Martínez-García M, et al. (2020) [53]2020Italyretrospective341640.53065.7 ± 14.4Martinez-García MA, et al. (2021) [54]2021Spainretrospective14919120.63967.6 ± 15.2McDonnell MJ, et al. (2015) [56]2015UKretrospective101550.60662.1 ± 12.4Mehra S, et al. (2021) [57]2021Australiaretrospective673880.58559Menéndez R, et al. (2017) [58]2017Spainprospective262650.60069.9Munteanu O, et al. (2016) [59]2016Moldovaprospective71650.44056.73 ± 14Olveira C, et al. (2017) [60]2017Spainretrospective11017920.54964.9 ± 18.4Pieters A, et al. (2019) [61]2019Netherlandsretrospective102110.54060Polverino E, et al. (2024) [62]2024Europeprospective526716,9630.60967.38Rademacher J, et al. (2019) [63]2019Germanyprospective11010000.59059 ± 16Rosales-Mayor E, et al. (2017) [64]2017Spainretrospective221820.59968.0 ± 14.6Scioscia G, et al. (2019) [65]2019Spainprospective131910.56572Venning V, et al. (2017) [68]2017Australiaretrospective27610.56066 ± 14Xu JF, et al. (2025) [69]2025Chinaprospective55810,3240.58263.1 ± 14.2Young SL, et al. (2021) [70]2021Singaporeprospective151680.67864 Characteristics of asthma and bronchiectasis studies included in this meta-analysis Pooled proportion of COPD among patients with bronchiectasis The pooled proportion of COPD among patients with bronchiectasis was 18%, with a random-effects pooled estimate of 0.18 (95% CI 0.14–0.22). In comparison, the fixed-effects model yielded a pooled estimate of 0.15 (95% CI 0.14–0.15). Substantial heterogeneity was observed among the included studies (I² = 99.4%, P = 0) (Fig. 2). Fig. 2Proportion of bronchiectasis–COPD overlap in patients with bronchiectasis. CI, confidence interval Proportion of bronchiectasis–COPD overlap in patients with bronchiectasis. CI, confidence interval Pooled proportion of asthma among patients with bronchiectasis The pooled proportion of asthma among patients with bronchiectasis was 16%, with a random-effects pooled estimate of 0.16 (95% CI 0.11–0.20). The fixed-effects model produced a pooled estimate of 0.09 (95% CI 0.09–0.09). Significant heterogeneity was also observed among the studies (I² = 99.3%, P = 0) (Fig. 3). Fig. 3Proportion of bronchiectasis–asthma overlap in patients with bronchiectasis. CI, confidence interval Proportion of bronchiectasis–asthma overlap in patients with bronchiectasis. CI, confidence interval Subgroup analyses Subgroup analyses were conducted to explore potential sources of heterogeneity based on geographic region, study design, and participant age. In the regional subgroup analysis, studies conducted in Oceania showed the highest proportion of COPD coexisting with bronchiectasis, with a pooled proportion of 57% (I2 = 0%, P = 0.70), while the pooled proportion of asthma coexistence in this region was 30% (I2 = 93.9%, P < 0.0001) (Figs. 4 and 5). In contrast, studies conducted in Europe showed the lowest proportions, with COPD coexistence estimated at 15% (I2 = 98.6%, P = 0) and asthma coexistence at 14% (I2 = 99.5%, P = 0). Fig. 4Subgroup analysis by region - proportion of bronchiectasis–COPD overlap in patients with bronchiectasis. Geographic regions = 1: Asia; Geographic regions = 2: Europe; Geographic regions = 3: North America; Geographic regions = 4: Oceania Subgroup analysis by region - proportion of bronchiectasis–COPD overlap in patients with bronchiectasis. Geographic regions = 1: Asia; Geographic regions = 2: Europe; Geographic regions = 3: North America; Geographic regions = 4: Oceania Fig. 5Subgroup analysis by region - proportion of bronchiectasis–asthma overlap in patients with bronchiectasis. Geographic regions = 1: Asia; Geographic regions = 2: Europe; Geographic regions = 3: North America; Geographic regions = 4: Oceania Subgroup analysis by region - proportion of bronchiectasis–asthma overlap in patients with bronchiectasis. Geographic regions = 1: Asia; Geographic regions = 2: Europe; Geographic regions = 3: North America; Geographic regions = 4: Oceania When stratified by study design, retrospective studies reported higher proportions of coexistence than prospective studies. The pooled proportion of COPD among bronchiectasis patients was 21% (I2 = 99.5%, P = 0) in retrospective studies compared with 14% (I2 = 99.1%, P = 0) in prospective studies (Figs. 6). Similarly, the pooled proportion of asthma was 18% (I2 = 97.8%, P < 0.0001) in retrospective studies and 12% (I2 = 99.7%, P = 0) in prospective studies (Figs. 7). Fig. 6Subgroup analysis by study type - proportion of bronchiectasis–COPD overlap in patients with bronchiectasis. Study.design = 1: prospective; Study.design = 2: retrospective Subgroup analysis by study type - proportion of bronchiectasis–COPD overlap in patients with bronchiectasis. Study.design = 1: prospective; Study.design = 2: retrospective Fig. 7Subgroup analysis by study type - proportion of bronchiectasis–asthma overlap in patients with bronchiectasis. Study.design = 1: prospective; Study.design = 2: retrospective Subgroup analysis by study type - proportion of bronchiectasis–asthma overlap in patients with bronchiectasis. Study.design = 1: prospective; Study.design = 2: retrospective Subgroup analysis based on age demonstrated that the pooled proportion of COPD coexistence was 18% (I2 = 99.3%, P = 0) in studies with a mean participant age ≥ 65 years and 21% (I2 = 98.9%, P < 0.0001) in studies with a mean age < 65 years (Figs. 8). For asthma coexistence, the pooled proportion was 20% (I2 = 99.6%, P = 0) in studies with a mean age ≥ 65 years and 11% (I2 = 97.6%, P < 0.0001) in those with a mean age < 65 years (Figs. 9). Fig. 8Subgroup analysis by age - proportion of bronchiectasis–COPD overlap in patients with bronchiectasis. age = 1: age ≥ 65; age = 2: age<65 Subgroup analysis by age - proportion of bronchiectasis–COPD overlap in patients with bronchiectasis. age = 1: age ≥ 65; age = 2: age<65 Fig. 9Subgroup analysis by age - proportion of bronchiectasis–asthma overlap in patients with bronchiectasis. age = 1: age ≥ 65; age = 2: age<65 Subgroup analysis by age - proportion of bronchiectasis–asthma overlap in patients with bronchiectasis. age = 1: age ≥ 65; age = 2: age<65 Publication bias and sensitivity analysis Publication bias and the stability of the pooled estimates were assessed using funnel plots, Egger’s regression test, and sensitivity analyses. Visual inspection of the funnel plots for both COPD and asthma analyses suggested an approximately symmetrical distribution of the included studies (Figure S1). Egger’s test further confirmed the absence of significant publication bias (COPD: t = 0.67, P = 0.506; asthma: t = 1.45, P = 0.153). Sensitivity analyses using a leave-one-out approach demonstrated that the pooled estimates were stable, as the exclusion of any single study did not materially alter the overall results (Figure S2).Given that several included studies drew from the same national registries, an additional sensitivity analysis was conducted to assess the potential impact of partial patient overlap. After simultaneously excluding three studies derived from the Spanish Historical Registry of Bronchiectasis [28, 50, 60], the pooled estimates remained essentially unchanged. For COPD, the proportion shifted minimally from 18% (95% CI: 14–22%) to 18.7% (95% CI: 14.8–22.7%); for asthma, from 16% (95% CI: 11–20%) to 16.1% (95% CI: 11.7–20.5%). These negligible changes confirm that potential patient duplication did not materially influence our findings. Overall, these findings indicate that the pooled estimates are stable with respect to individual study influence and unlikely to be substantially affected by publication bias. Meta-regression analyses To explore sources of heterogeneity, meta-regression analyses were performed examining the effects of mean age, publication year, geographic region, study design, and female proportion. Results are presented in Tables 3 and 4. Table 3Meta-regression analyses of factors influencing the proportion of COPD in bronchiectasis patientsCovariateCoefficient (β)95% CIP-valueMean age0.021-0.018 to 0.0600.294Publication year0.03-0.034 to 0.0940.351Geographic region0.294-0.112 to 0.7010.156Study design0.292-0.332 to 0.9150.359Female proportion1.888-0.646 to 4.4220.144CI confidence interval. All analyses were performed using a random-effects model (REML) Table 3Meta-regression analyses of factors influencing the proportion of COPD in bronchiectasis patientsCovariateCoefficient (β)95% CIP-valueMean age0.021-0.018 to 0.0600.294Publication year0.03-0.034 to 0.0940.351Geographic region0.294-0.112 to 0.7010.156Study design0.292-0.332 to 0.9150.359Female proportion1.888-0.646 to 4.4220.144CI confidence interval. All analyses were performed using a random-effects model (REML) Meta-regression analyses of factors influencing the proportion of COPD in bronchiectasis patients CI confidence interval. All analyses were performed using a random-effects model (REML) Table 4Meta-regression analyses of factors influencing the proportion of asthma in bronchiectasis patientsCovariateCoefficient (β)95% CIP-valueMean age0.025-0.028 to 0.0780.346Publication year-0.018-0.078 to 0.0420.554Geographic region0.281-0.080 to 0.6430.127Study design0.281-0.233 to 0.7960.284Female proportion 3.97 0.906 to 7.033 0.011 CI confidence interval. All analyses were performed using a random-effects model (REML). Bold text indicates statistical significance (P < 0.05) Table 4Meta-regression analyses of factors influencing the proportion of asthma in bronchiectasis patientsCovariateCoefficient (β)95% CIP-valueMean age0.025-0.028 to 0.0780.346Publication year-0.018-0.078 to 0.0420.554Geographic region0.281-0.080 to 0.6430.127Study design0.281-0.233 to 0.7960.284Female proportion 3.97 0.906 to 7.033 0.011 CI confidence interval. All analyses were performed using a random-effects model (REML). Bold text indicates statistical significance (P < 0.05) Meta-regression analyses of factors influencing the proportion of asthma in bronchiectasis patients CI confidence interval. All analyses were performed using a random-effects model (REML). Bold text indicates statistical significance (P < 0.05) For COPD prevalence, none of the covariates showed statistically significant associations. Female proportion showed a positive but non-significant coefficient (β = 1.888, 95% CI: -0.646 to 4.422; P = 0.144), and similar null findings were observed for mean age (P = 0.294), publication year (P = 0.351), geographic region (P = 0.156), and study design (P = 0.359). These factors explained minimal between-study variance (R² = 0.0–2.6%), indicating that the high heterogeneity in COPD prevalence remains largely unexplained (Table 3). For asthma prevalence, female proportion showed a statistically significant positive association (β = 3.97, 95% CI: 0.906 to 7.033; P = 0.011) (Table 4). This relationship is visualized in the bubble plot (Fig. 10). However, this covariate explained only 10.6% of the between-study heterogeneity, indicating that the vast majority of variability in asthma prevalence across studies is attributable to other, unmeasured factors. Other covariates—mean age (P = 0.346), publication year (P = 0.554), geographic region (P = 0.127), and study design (P = 0.284)—showed no significant associations. Fig. 10Bubble plot of meta-regression for the proportion of asthma. Bubble plot showing the relationship between the proportion of female participants and the proportion of asthma (logit-transformed) in patients with bronchiectasis. The size of each bubble is proportional to the study’s precision (inverse of the variance). The solid red line represents the meta-regression line, and the dashed lines indicate the 95% confidence interval. The plot illustrates a significant positive association (β = 3.97, 95% CI: 0.91 to 7.03, P = 0.011) Bubble plot of meta-regression for the proportion of asthma. Bubble plot showing the relationship between the proportion of female participants and the proportion of asthma (logit-transformed) in patients with bronchiectasis. The size of each bubble is proportional to the study’s precision (inverse of the variance). The solid red line represents the meta-regression line, and the dashed lines indicate the 95% confidence interval. The plot illustrates a significant positive association (β = 3.97, 95% CI: 0.91 to 7.03, P = 0.011) Discussion Bronchiectasis is increasingly recognized as a major chronic airway disease characterized by irreversible bronchial dilation and a persistent cycle of infection and inflammation [78]. In the present meta-analysis, we demonstrated that chronic obstructive pulmonary disease (COPD) and asthma coexist in 18% and 16% of patients with bronchiectasis, respectively. These estimates are broadly consistent with previous observational studies and meta-analyses reporting substantial overlap between chronic airway diseases, although the exact proportions have varied considerably across cohorts. For instance, prior pooled analyses have suggested that the prevalence of bronchiectasis among patients with COPD may range from 25% to over 50%, particularly in severe disease populations [13, 14], while studies in asthma cohorts have reported bronchiectasis prevalence rates approaching one-third in severe cases [8, 9]. Our findings extend this body of evidence by shifting the perspective to the bronchiectasis population itself and providing a more comprehensive estimate of the bidirectional overlap, thereby reinforcing the concept that these conditions frequently coexist across different clinical contexts. Notably, the largest and most contemporary single data source included in our analysis——the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) registry (n = 16,963)——reported an asthma prevalence of 31.0% [62], which is nearly double our pooled estimate of 16%. This marked discrepancy likely reflects several factors. First, our pooled estimate incorporates a substantial number of studies from Asia, where reported asthma prevalence among bronchiectasis patients is consistently lower than in Europe: the Chinese Bronchiectasis Registry (BE-China, n = 10,324) reports asthma in only 5.4% of patients [69], the Korean KMBARC registry (n = 598) in 5.0% [46], and the Indian Bronchiectasis Registry (n = 2,195) in just 2.5% [31]. These figures contrast sharply with European data, where the Spanish RIBRON registry (n = 2,615) reports 7.8% [54] and the US Bronchiectasis Research Registry (n = 1,085) reports 29% as asthma etiology [30]. The inclusion of these large, lower-prevalence cohorts pulls the overall pooled estimate substantially downward. Second, diagnostic practices and labeling conventions for asthma differ markedly across regions; what is classified as asthma in one setting may be recorded as “reversible airflow obstruction” or “bronchial hyperresponsiveness” in another. Third, the EMBARC registry represents a contemporaneous, systematically characterized European cohort with prospective data collection and investigator-reported diagnoses, potentially capturing asthma more completely than older or retrospectively conducted studies. Importantly, when asthma is considered as a comorbidity rather than an etiology——the approach used in EMBARC——prevalence figures tend to be considerably higher (EMBARC: 31.0%) than when asthma is classified strictly as the causative etiology of bronchiectasis (EMBARC: 6.9%) [62]. The included studies in our analysis employed heterogeneous definitions, with some reporting asthma as an etiology and others as a comorbidity, further contributing to the divergence from EMBARC’s comorbidity-based estimate. Therefore, rather than representing a true contradiction, the lower pooled estimate primarily reflects the weighted influence of Asian cohorts with low asthma prevalence, the inclusion of older studies with varying diagnostic criteria, and the blending of etiological and comorbid definitions of asthma across the analyzed literature. The observed bronchiectasis–COPD overlap is supported by well-established shared pathogenic pathways, which have been extensively described in the literature. Smoking is an established major risk factor for COPD, and smoking-related airway injury is recognized as a central mechanism linking COPD to secondary bronchiectasis through chronic inflammation, structural damage, and impaired host defense [79–81]. While smoking is not consistently established as an independent cause of bronchiectasis in the absence of COPD, it likely contributes to disease progression in the context of bronchiectasis–COPD overlap. With regard to the pathophysiological aspects, neutrophils and T lymphocytes are pivotal in the inflammatory response in chronic airway diseases. Neutrophils emit proteases, disrupting the balance between proteases and anti-proteases, leading to lung tissue degradation. T lymphocytes induce peribronchial lymph node enlargement and persistent airway inflammation, exacerbating airflow obstruction [6, 82]. Furthermore, enhanced mucus secretion and the damage or destruction of ciliated cells in dilated airways foster bacterial colonization or chronic infection. This perpetuates bronchial wall damage, creating a detrimental cycle of infection and airway harm [83, 84]. Alpha-1 antitrypsin deficiency, linked to elevated COPD risk, is also associated with bronchiectasis by a mechanism linked to changes in neutrophil elastase activity levels [85, 86]. In COPD patients, mucus hypersecretion contributes to airway blockage, with mucociliary clearance notably impaired in severe cases [87]. Heightened mucin levels in bronchiectasis patients’ sputum lead to mucociliary damage and heightened infection susceptibility [88, 89]. We propose that these observations suggest similarities in the pathophysiological mechanisms of these two diseases. In addition, earlier meta-analyses have demonstrated that patients with bronchiectasis–COPD overlap exhibit worse clinical outcomes, including higher exacerbation frequency, greater sputum production, and increased systemic inflammation compared with COPD alone [13, 14]. Taken together, these data support the notion that bronchiectasis–COPD overlap represents a distinct and clinically significant phenotype, rather than a coincidental coexistence, and our results further quantify the magnitude of this overlap from the bronchiectasis perspective. Bronchiectasis–asthma overlap, although less extensively characterized, has also been increasingly reported [17]. Previous studies have highlighted that bronchiectasis is more common in patients with severe or corticosteroid-dependent asthma [90, 91], suggesting that chronic airway inflammation and impaired immune responses may contribute to structural airway damage. Although the relationship between bronchiectasis and asthma remains controversial, it is clear that these two diseases interact in their pathogenesis. Bronchiectasis, often marked by recurrent respiratory infections and increased bronchial secretions, exacerbates airflow limitations, leading to asthma’s paroxysmal symptoms. Notably, neutrophilic inflammation in asthma is known to cause airway epithelial damage and intensify structural damage in the bronchi [92, 93]. In the inflammatory response characteristic of asthma, eosinophilia and type 2 T helper cell-mediated inflammation are predominant. A study analyzing sputum cells from bronchiectasis patients revealed a significant presence of neutrophils, with 69% of samples having neutrophil levels above 64% and 20% showing eosinophil counts equal to or greater than 3% [94]. Notably, our meta-regression analysis identified female proportion as a statistically significant but weak predictor of asthma prevalence in bronchiectasis populations. Although this finding aligns with the well-documented female predominance in adult asthma [95, 96], the association explained only a small fraction of the between-study heterogeneity. This observation adds an additional layer to existing literature by suggesting that sex distribution may partially account for variability in reported asthma prevalence across bronchiectasis cohorts, a factor that has been largely underexplored in previous studies. The biological plausibility of this association is supported by several lines of evidence. Estrogen and progesterone are known to modulate type 2 immune responses, enhancing eosinophilic inflammation, mast cell activation, and airway hyperresponsiveness [95, 96]. Sex-related differences in airway remodeling—including increased airway wall thickness and altered smooth muscle function in women—have been documented in both asthma and bronchiectasis [96]. Furthermore, asthma in women is often characterized by later onset and a non-allergic, obesity-associated phenotype, which may be particularly prone to overlapping structural airway damage. In the context of bronchiectasis, underrecognized or undertreated asthma phenotypes in women may contribute to a higher observed comorbidity burden. However, as our meta-regression model explained only 10.6% of between-study variance, sex distribution alone cannot account for the majority of heterogeneity. The substantial residual heterogeneity (89.4%) likely reflects unmeasured confounders that could not be captured at the study level, including between-study differences in smoking prevalence, asthma severity, atopy rates, diagnostic protocols, and healthcare access. Individual participant data meta-analysis would be required to disentangle the independent contribution of sex from these interrelated factors. A key methodological observation in this study is the presence of substantial heterogeneity across included studies, with I² values exceeding 99% for both COPD and asthma prevalence. This degree of heterogeneity is not unexpected and is consistent with previous meta-analyses in bronchiectasis research, where variability in study populations and methodologies frequently leads to high between-study variance [97, 98]. Despite the use of subgroup analyses and meta-regression, most examined covariates—including age, region, and study design—did not significantly explain this heterogeneity, suggesting that important sources of variability remain unmeasured. Prior studies have similarly noted that differences in diagnostic criteria, disease severity, imaging protocols, and healthcare settings can substantially influence reported prevalence rates. Therefore, the heterogeneity observed in this analysis likely reflects both methodological diversity and the intrinsic clinical heterogeneity of bronchiectasis as a disease entity, rather than simply indicating statistical inconsistency. Importantly, in meta-analyses of proportions that include large-scale registry studies with very high precision, the I² statistic can approach its maximum value as a statistical artifact rather than reflecting purely clinical inconsistency. When individual studies report proportions with extremely narrow confidence intervals due to large sample sizes, even small absolute differences between studies can yield near-maximal I² values, because the fixed-effect assumption of a single true proportion is easily rejected. Thus, the reported I² values should be interpreted with caution; the random-effects model appropriately accounts for this variability, and the confidence intervals of the pooled estimates provide the most reliable indication of precision. Nevertheless, the substantial residual heterogeneity also underscores the genuine clinical and methodological diversity among bronchiectasis populations worldwide, including differences in diagnostic criteria, disease severity, healthcare settings, and geographic factors [99].Consequently, the pooled estimates reported here should be interpreted as approximate statistical summaries of the available literature rather than as stable, universally applicable population parameters. The extreme heterogeneity limits direct clinical generalizability, and the true prevalence of COPD and asthma comorbidity in any specific bronchiectasis population may differ substantially from these global averages depending on local demographic, diagnostic, and healthcare system factors. The subgroup findings observed in this study should also be interpreted in the context of existing literature. The higher prevalence reported in retrospective studies is consistent with previous observations that retrospective cohorts often include more severe or selected patient populations, potentially leading to overestimation of comorbidity rates [100]. Regional differences, including the higher prevalence observed in Oceania and lower rates in Europe, may reflect disparities in study availability, diagnostic practices, and healthcare systems rather than true epidemiological differences, a phenomenon also noted in earlier global bronchiectasis studies. The 57% pooled prevalence of COPD among bronchiectasis patients in Oceania warrants particular caution in interpretation. This estimate is derived from only three studies (one from a regional Australian center and two from metropolitan hospitals) and is heavily weighted by two studies with exceptionally high COPD rates. The study by Mehra et al. (2021) included a cohort from the Northern Territory of Australia in which 66% of participants were Aboriginal Australians—a population known to experience a disproportionately high burden of bronchiectasis and COPD [57]. In that cohort, the COPD co-prevalence was 56.4%, substantially exceeding global averages. Similarly, the study by Venning et al. (2017) reported a COPD prevalence of 59% among patients hospitalized with infective exacerbations of bronchiectasis at an Australian metropolitan hospital [68]. The high burden of chronic respiratory disease among First Nations and Indigenous populations in Australia and New Zealand is well documented: Aboriginal Australians have a COPD prevalence approximately 2.5 times that of non-Indigenous Australians, and New Zealand Maori and Pacific Islanders experience both higher incidence and greater severity of bronchiectasis compared with European-descended populations [101]. Consequently, the 57% figure should not be interpreted as representative of the general Oceania population but rather as a reflection of the specific high-risk populations and clinical settings captured by the limited number of studies in this region. Future studies with broader population-based sampling from Oceania are needed to provide more generalizable estimates. Similarly, age-related differences in prevalence have been inconsistently reported in the literature, and our findings, together with the lack of significant associations in meta-regression, suggest that these patterns may be confounded by study design and population characteristics rather than representing independent risk factors. From a clinical perspective, the high prevalence of COPD and asthma among patients with bronchiectasis aligns with previous evidence demonstrating that overlap syndromes are associated with worse clinical outcomes, including increased exacerbation risk, reduced lung function, and poorer quality of life [13–16]. These findings underscore the importance of systematically evaluating for coexisting airway diseases in patients with bronchiectasis, particularly given the potential for misclassification due to overlapping symptoms and spirometric features. Early identification of overlap phenotypes may facilitate more targeted therapeutic strategies, including the optimized use of inhaled corticosteroids, bronchodilators, and infection control measures. However, the high prevalence figures reported in our meta-analysis should be interpreted in light of potential diagnostic imprecision. The recently proposed ROSE criteria (Radiological bronchiectasis, Obstruction [FEV₁/FVC < 0.7], Symptoms, and Exposure [≥ 10 pack-years of smoking]) provide an objective, standardized framework for defining the association between bronchiectasis and COPD. When these criteria were retrospectively applied to the European Bronchiectasis Registry (EMBARC), 22.2% of patients assigned a clinical label of COPD were found to lack spirometric evidence of airflow obstruction, and 31.9% had no significant smoking history, indicating marked overdiagnosis. The included studies in our meta-analysis span several decades and many did not employ such standardized definitions; therefore, some proportion of the reported COPD and asthma comorbidity may reflect diagnostic labeling rather than confirmed disease. This underscores the need for objective assessment—including spirometry and exposure history—when evaluating patients with bronchiectasis for coexisting airway diseases [102, 103]. In addition, although the observed association between female sex and asthma prevalence was weak and explained limited heterogeneity, sex-specific factors may still warrant consideration in clinical assessment, particularly given the known female predominance in adult asthma. This area merits further investigation in studies with individual-level data. However, the study is not without its limitations. A significant heterogeneity among the included studies was observed, likely influenced by multiple methodological factors. First, our search was restricted to English-language publications, which may have excluded relevant studies from non-English-speaking regions and introduced language bias. Consistent with this, no eligible studies from Latin America or Africa were identified in our search. Given that the etiology and prevalence of bronchiectasis, as well as the epidemiology of COPD and asthma, vary substantially by region and socioeconomic context, the absence of data from these regions limits the global generalizability of our estimates. This heterogeneity might have impacted the consistency of results. Second, given that most bronchiectasis patients exhibit airflow limitations, there is often a misdiagnosis as COPD due to similar lung function alterations. This issue is highlighted by recent EMBARC data demonstrating that 22.2% of bronchiectasis patients with a physician-assigned COPD diagnosis do not meet spirometric criteria for airflow obstruction when assessed using the ROSE criteria. The lack of consistent spirometric confirmation for COPD and standardized diagnostic criteria for asthma across included studies may have contributed to over- or underestimation of overlap proportions. This overlap complicates the determination of disease onset sequence and poses challenges in distinguishing the primary diagnosis. Third, we were unable to stratify our analyses by healthcare setting (e.g., primary care, secondary care, tertiary referral centers, or inpatient cohorts) because the majority of included studies did not consistently report the recruitment source or level of care. This is a notable limitation, as cohorts drawn from tertiary referral centers are likely enriched for more severe or complex disease and may overestimate comorbidity rates due to referral bias. Conversely, population-based or primary care cohorts may yield lower estimates that better reflect the general bronchiectasis population. The inability to account for this source of heterogeneity may partially explain the wide variation in reported prevalence and the high residual I² values. Future primary studies should routinely document the healthcare setting to enable more refined meta-analyses. Fourth, several included studies drew from the same national registries—specifically, three studies from the Spanish Historical Registry of Bronchiectasis—and although our sensitivity analysis confirmed that potential patient duplication had negligible impact, this remains a methodological consideration for future meta-analyses. Fifth, the lack of detailed clinical data restricts further analysis of critical aspects like lung function and sputum volume. Such information could have provided a more comprehensive understanding of the disease profiles. Therefore, future epidemiological studies with larger sample sizes are necessary to deepen our understanding of these diseases. Furthermore, exploring the interactions between chronic airway diseases in more depth will be a valuable area for future research. Conclusion In conclusion, this meta-analysis provides evidence that COPD and asthma frequently coexist in patients with bronchiectasis, supporting the concept of overlapping airway disease phenotypes. By integrating findings from previous studies with a comprehensive quantitative synthesis, our results highlight the need for a more holistic, phenotype-driven approach to the diagnosis and management of chronic airway diseases. To reduce misclassification, we recommend that future studies employ standardized post-bronchodilator spirometry with strict adherence to GOLD criteria—including documentation of smoking history and symptom assessment—when diagnosing COPD in patients with bronchiectasis. Future research incorporating standardized definitions and individual-level data will be essential to further elucidate the mechanisms and clinical implications of these complex bronchiectasis–COPD and bronchiectasis–asthma overlap phenotypes. Supplementary Information Supplementary Material 1. Supplementary Material 1.